Literature DB >> 26370918

Baseline Antihypertensive Drug Count and Patient Response to Hypertension Medication Management.

Matthew J Crowley1,2, Maren K Olsen1,3, Sandra L Woolson1, Heather A King1,4, Eugene Z Oddone1,4, Hayden B Bosworth1,4.   

Abstract

Telemedicine-based medication management improves hypertension control, but has been evaluated primarily in patients with low antihypertensive drug counts. Its impact on patients taking three or more antihypertensive agents is not well-established. To address this evidence gap, the authors conducted an exploratory analysis of an 18-month, 591-patient trial of telemedicine-based hypertension medication management. Using general linear models, the effect of medication management on blood pressure for patients taking two or fewer antihypertensive agents at study baseline vs those taking three or more was compared. While patients taking two or fewer antihypertensive agents had a significant reduction in systolic blood pressure with medication management, those taking three or more had no such response. The between-subgroup effect difference was statistically significant at 6 months (-6.4 mm Hg [95% confidence interval, -12.2 to -0.6]) and near significant at 18 months (-6.0 mm Hg [95% confidence interval, -12.2 to 0.2]). These findings suggest that baseline antihypertensive drug count may impact how patients respond to hypertension medication management and emphasize the need to study management strategies specifically in patients taking three or more antihypertensive medications. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26370918      PMCID: PMC4792789          DOI: 10.1111/jch.12669

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  22 in total

1.  Incidence and prognosis of resistant hypertension in hypertensive patients.

Authors:  Stacie L Daugherty; J David Powers; David J Magid; Heather M Tavel; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Joe V Selby; P Michael Ho
Journal:  Circulation       Date:  2012-02-29       Impact factor: 29.690

2.  Home blood pressure management and improved blood pressure control: results from a randomized controlled trial.

Authors:  Hayden B Bosworth; Benjamin J Powers; Maren K Olsen; Felicia McCant; Janet Grubber; Valerie Smith; Pamela W Gentry; Cynthia Rose; Courtney Van Houtven; Virginia Wang; Mary K Goldstein; Eugene Z Oddone
Journal:  Arch Intern Med       Date:  2011-07-11

3.  Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients.

Authors:  Luca De Nicola; Francis B Gabbai; Rajiv Agarwal; Paolo Chiodini; Silvio Borrelli; Vincenzo Bellizzi; Felice Nappi; Giuseppe Conte; Roberto Minutolo
Journal:  J Am Coll Cardiol       Date:  2013-04-23       Impact factor: 24.094

4.  Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial.

Authors:  Karen L Margolis; Stephen E Asche; Anna R Bergdall; Steven P Dehmer; Sarah E Groen; Holly M Kadrmas; Tessa J Kerby; Krissa J Klotzle; Michael V Maciosek; Ryan D Michels; Patrick J O'Connor; Rachel A Pritchard; Jaime L Sekenski; JoAnn M Sperl-Hillen; Nicole K Trower
Journal:  JAMA       Date:  2013-07-03       Impact factor: 56.272

5.  How well do clinic-based blood pressure measurements agree with the mercury standard?

Authors:  Jennifer W Kim; Hayden B Bosworth; Corrine I Voils; Maren Olsen; Tara Dudley; Matthew Gribbin; Martha Adams; Eugene Z Oddone
Journal:  J Gen Intern Med       Date:  2005-07       Impact factor: 5.128

6.  Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999-2010.

Authors:  Hoi Kin Wong; Kwok Leung Ong; Ching-Lung Cheung; Bernard M Y Cheung
Journal:  Ann Epidemiol       Date:  2014-05-10       Impact factor: 3.797

7.  Managing hypertension in urban underserved subjects using telemedicine--a clinical trial.

Authors:  Alfred A Bove; Carol J Homko; William P Santamore; Mohammed Kashem; Margaret Kerper; Daniel J Elliott
Journal:  Am Heart J       Date:  2013-03-06       Impact factor: 4.749

8.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

9.  Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Circulation       Date:  2008-06-24       Impact factor: 29.690

10.  Telemonitoring based service redesign for the management of uncontrolled hypertension: multicentre randomised controlled trial.

Authors:  Brian McKinstry; Janet Hanley; Sarah Wild; Claudia Pagliari; Mary Paterson; Steff Lewis; Aziz Sheikh; Ashma Krishan; Andrew Stoddart; Paul Padfield
Journal:  BMJ       Date:  2013-05-24
View more
  2 in total

1.  Utilising digital health to improve medication-related quality of care for hypertensive patients: An integrative literature review.

Authors:  Kannikar Wechkunanukul; Daya Ram Parajuli; Mohammad Hamiduzzaman
Journal:  World J Clin Cases       Date:  2020-06-06       Impact factor: 1.337

2.  Baseline Antihypertensive Drug Count and Patient Response to Hypertension Medication Management.

Authors:  Matthew J Crowley; Maren K Olsen; Sandra L Woolson; Heather A King; Eugene Z Oddone; Hayden B Bosworth
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-09-15       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.